Answers are grounded in this paper and cite their sources.
The gut microbiome critically modulates anti-tumor immunity, yet whether Akkermansia muciniphila (AKK) and Bifidobacterium breve (Bifido) act synergistically remains unknown. Here, we demonstrate that AKK monotherapy suppresses tumor growth in syngeneic murine colon cancer models while upregulating host Bifido levels. Co-administration of AKK and Bifido produces a reciprocal potentiation of anti-tumor activity exceeding either monotherapy. This combination significantly impairs tumor growth, enhances apoptosis, and increases CD4⁺ and CD8⁺ T cell infiltration. Metabolomic profiling revealed that AKK combined with Bifido specifically downregulates prostaglandin E2 (PGE2), which corresponds with marked COX-2 suppression predominantly in tumor cells. Functionally, exogenous PGE2 dose-dependently rescues tumor growth and abolishes the combined therapeutic efficacy. Conversely, COX-2 knockdown or pharmacological inhibition with Celebrex in tumor cells supresses basal tumor growth but neutralizes the additional benefit of combined probiotic therapy, identifying COX-2/PGE2 suppression as an essential mechanism driving this synergistic anti-tumor response. Together, these findings reveal a novelty cross-talk mechanism between Akk and Bifido via suppression of the COX-2/PGE2 axis in tumor cells, establishing a mechanistic rationale for multi-strain probiotic combinations in cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: